Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Ariceum Therapeutics GmbH’s radiopharmaceutical 225Ac-SSO110 ([225Ac]satoreotide tetraxetran) has been awarded orphan drug designation by the FDA for the treatment of small-cell lung cancer (SCLC).

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...